Factors affecting the urinary aldosterone-to-creatinine ratio in healthy dogs and dogs with naturally occurring myxomatous mitral valve disease

Table 3 Laboratory parameters in all dogs, healthy dogs and dogs with different stages of MMVD

	All dogs	Healthy	Stage B1	Stage B2	Stage C
Number	149	49	45	13	42
UREA (mg/dL)	39 (31–49.28)	33 (27.93–40-50) ^§	35.16 ± 10.60	58 ± 25.85	49 (38.68–68.04)
SCr (mg/dL)	0.92 (0.80–1.10)	0.91 ± 0.20	0.89 ± 0.18	1.04 ± 0.32	1 (0.80–1.18)
USG	1036 (1020.50–1052)	1046.98 ± 18.41 ^§	1042.07 ± 16.16 ^§	1039.69 ± 20.50	1019 (1011.50–1028.50)
UP/UC	0.12 (0.04–0.27)	0.07 (0.03–0.12) ^‡§	0.15 (0.06–0.24)	0.20 (0.10–0.41)	0.25 (0.35–0.69)
UAldo:C (μg/g)	1.86 (0.88–3.77)	1.75 (0.83–4.02)	1.75 (0.73–3.13)	1.95 (0.85–4.65)	2.03 (1.16–4.85)

UREA Serum urea, SCr Serum creatinine, USG Urine specific gravity, UP/UC Urinary protein-to-creatinine ratio, UAldo:C Urinary aldosterone-to-creatine ratio
Data are reported as mean ± standard deviation for normally distributed variables and median (interquartile range) for non-normally distributed variables
†values significantly differ (p < 0.05) from stage B1; ‡values significantly differ (p < 0.05) from stage B2; §values significantly differ (p < 0.05) from stage C

ISSN: 1746-6148